Full Press Release Details
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis.
ARGX
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis
Key Takeaway: argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis